All In Biotech

BLA 103362 · Berlex Labs

Leukine

Sargramostim · Leukocyte Growth Factor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 5, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Mar 5, 1991

Approved uses

5

Original approval plus efficacy supplements

Registered trials

660

64 Phase 3, 38 recruiting

FAERS reports

1,730

1,272 serious, 255 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 6, 2024.

LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) 1.1 Acute Myeloid Leukemia Following Induction Chemotherapy LEUKINE is indicated to shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). 1.2 Autologous Peripheral Blood Progenitor Cell Mobilization and Collection LEUKINE is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for...

Mechanism: Sargramostim (GM-CSF) belongs to a group of growth factors termed colony-stimulating factors which support survival, clonal expansion, and differentiation of hematopoietic progenitor cells. GM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells. GM-CSF is also capable of activating mature granulocytes and macrophages. GM-CSF is a multilineage factor and, in addition to dose-dependent effects on the myelomonocytic lineage, can promote the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 2018 Supplement 5240 · Efficacy · priority review OrphanLabelLetterReview
  • Dec 22, 1995 Supplement 1045 · Efficacy
  • Nov 24, 1995 Supplement 1048 · Efficacy
  • Sep 15, 1995 Supplement 1033 · Efficacy
  • Mar 5, 1991 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • LEUKINE · SARGRAMOSTIM 250UG/ML · VIAL, · Prescription
  • LEUKINE · SARGRAMOSTIM 500UG/ML · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sargramostim" as an intervention, any sponsor and status, largest first.

All 660 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia158
  • off label use155
  • nausea128
  • pain113
  • hypotension111
  • dyspnoea110
  • fatigue94
  • diarrhoea87
  • death84
  • vomiting83
  • dizziness63
  • chills57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200547
200678
200765
2008167
200958
201068
2011128
2012142
201392
201458
201557
201678
201767
201872
201948
202039
2021107
202276
202362
202445
202568
202666

Recalls

1 FDA enforcement reports for this application.

  • Jun 23, 2021 · Class III · Terminated

    FAILED STABILITY SPECIFICATION: Out-of-specification (OOS) result observed for Leukine (sargramostim) at the 27-month stability timepoint.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Leukine (Sargramostim)

2024 spending

$3.3M

Beneficiaries

89

456 claims

Per beneficiary

$37,091

$303.41 per unit

View as table
YearSpending
2020$0
2021$3,233,408
2022$3,645,063
2023$3,139,334
2024$3,301,073

Part B: Leukine (Sargramostim) · HCPCS J2820

2024 spending

$1.4M

Beneficiaries

198

2,540 claims

Per beneficiary

$7,085

2024 ASP limit $59.76 per unit

View as table
YearSpending
2020$2,778,909
2021$2,351,486
2022$1,974,305
2023$1,867,290
2024$1,402,912

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Berlex Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.